Clinical Trials Logo

Vasculitis clinical trials

View clinical trials related to Vasculitis.

Filter by:
  • Withdrawn  
  • Page 1

NCT ID: NCT02418273 Withdrawn - Osteoporosis Clinical Trials

Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders

Start date: August 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to evaluate denosumab as a novel treatment for bone loss in children treated with glucocorticoids for rheumatic disorders. This is a pilot Phase 1/2, randomized open-label, 12-month clinical trial of denosumab to assess its effect on bone resorption markers and bone mineral density (BMD) in children with rheumatic disorders, age 4 to 16 years, recruited within 1 month of starting a chronic systemic glucocorticoid regimen. Primary outcomes include suppression of bone turnover markers and safety assessments. Secondary outcomes include changes in bone density as measured by dual energy X-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) densitometry at the radius and tibia.

NCT ID: NCT01598857 Withdrawn - Clinical trials for Microscopic Polyangiitis

BIANCA-SC: A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA-Associated Small Vessel Vasculitis

BIANCA-SC
Start date: December 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate efficacy, safety and tolerability of blisibimod when taken with methotrexate in the induction of remission in ANCA-Associated Small Vessel Vasculitis.

NCT ID: NCT01275287 Withdrawn - Clinical trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

Start date: May 2011
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to see if Eculizumab (Soliris®) can safely be used in addition to conventional therapy in patients with active ANCA (Antineutrophil Cytoplasmic Autoantibodies ) vasculitis and lead to a more rapid decrease in disease activity. ANCA vasculitis is an inflammation of the small vessels whereby ANCA antibodies inappropriately activate one's own white blood cells (neutrophils) and cause damage to the small blood vessels.

NCT ID: NCT01275274 Withdrawn - Clinical trials for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis

Retinoids in ANCA Small Vessel Vasculitis: Silencing Autoantigens

Start date: January 2012
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to learn if adding all-trans retinoic acid (tretinoin) to conventional treatment of Anti- Neutrophil Cytoplasmic Autoantibodies (ANCA) vasculitis can decrease the level of disease activity.